[CAS NO. 160162-42-5] SR11302
PRODUCTS SPECIFICATIONS [160162-42-5]
DESCRIPTION [160162-42-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 376.53 |
| Molecular Formula | C26H32O2 |
| SMILES | O=C(O)/C=C(C)/C=C/C=C(C1=CC=C(C)C=C1)/C=C/C2=C(C)CCCC2(C)C |
4 Publications Citing Use of MCE
Summary
IC50 & Target
AP-1 [1]
In Vitro
SR 11302 (SR11302) show strong anti-AP-1 activity with selective binding with RARα and RARγ, but not with RARβ and RXRα
[1]
.
SR 11302 (SR-11302; 1 μM) inhibits AP-1 transcription factor activity and decreases aldosterone levels by 61.9% in hypoxia-treated cells
[2]
.
SR 11302 (SR-11302; 2 µM; 48 hours) inhibits
Helicobacter pylori
(
H. pylori
)-induced cell proliferation in adenocarcinoma gastric (AGS) cells
[3]
.
SR 11302 (2 µM; 24 hours) inhibits
H. pylori
-induced expression of β-catenin and c-myc in AGS cells
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SR 11302 (SR11302; low dose 0.5 mg/kg and high dose 1 mg/kg body weight; orally gavaged daily) treatment reduces the total vascular lesion number and lesion size in Vldlr -/- mice in a dose-dependent manner [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Vldlr -/- mice [4] |
| Dosage: | Low dose 0.5 mg/kg and high dose 1 mg/kg body weight |
| Administration: | Orally gavaged daily from P5 to P15 |
| Result: | High-dose from P5 to P15 reduced the total vascular lesion number by 48% and decreased the lesion size by 40%, without detectable signs of toxicity in mice, including no change in body weight. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 66.40 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6558 mL | 13.2792 mL | 26.5583 mL |
| 5 mM | 0.5312 mL | 2.6558 mL | 5.3117 mL |
| 10 mM | 0.2656 mL | 1.3279 mL | 2.6558 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (6.64 mM); Suspended solution; Need ultrasonic
References
- [1] C Huang, et al. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5826-30.
- [2] Bradley A Maron, et al. Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation. 2014 Jul 8;130(2):168-79.
- [3] Eunyoung Byun, et al. Activation of NF-κB and AP-1 Mediates Hyperproliferation by Inducing β-Catenin and c-Myc in Helicobacter pylori-Infected Gastric Epithelial Cells. Yonsei Med J. 2016 May;57(3):647-51.
- [4] Ye Sun, et al. Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. J Exp Med. 2017 Jun 5;214(6):1753-1767.